Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Abstract: A control system for an internal combustion engine wherein fuel injection timing is determined according to a detected engine operating condition. An actual ignition timing of the fuel is detected and an ignition delay correction amount is calculated wherein the actual ignition timing coincides with a target ignition timing set according to the engine operating condition. A cetane number of the fuel is estimated using a plurality of conversion tables for converting the ignition delay correction amount to the cetane number of the fuel. The fuel injection timing is corrected with the ignition delay correction amount. An exhaust gas recirculation control value map used for calculating a control value of the recirculation amount of exhaust gases is switched according to the estimated cetane number. The conversion table used for estimating the cetane number is switched according to the estimated cetane number.

Abstract: A control system for an internal combustion engine having a fuel injection valve. A fuel injection timing is determined according to the detected engine operating condition. A target ignition timing of the fuel is calculated using a plurality of maps that store the target ignition timings according to the engine operating condition and an actual ignition timing of the fuel is detected. An ignition delay of the actual ignition timing with respect to the target ignition timing is calculated. The cetane number of the fuel is estimated according to the calculated ignition delay. The map to be used in calculating the target ignition timing is switched according to the estimated cetane number.

Abstract: An in-cylinder pressure detection device which is capable of ensuring stable detection accuracy irrespective of tightening torque applied in mounting the in-cylinder pressure detection device and thermal expansion of component parts of the same. A housing 21 has a top wall 22a and a bottom wall 22b opposed to each other, and is screwed into the body of an internal combustion engine. An inner member 24 extends through the housing 21 such that one end thereof projects into a cylinder C, and has a flange part 24b accommodated in the housing 21. A first piezoelectric element 11c is accommodated in the housing 21 and sandwiched between the bottom wall 22b and the flange part 24b in a preloaded state, for outputting a first detection signal q1 according to the in-cylinder pressure transmitted via the inner member 24.

Abstract: A control system for an internal combustion engine having fuel injection valves provided in a combustion chamber and an exhaust gas recirculation mechanism. Target maximum cylinder pressure change rates are set according to the operating condition of the engine. The maximum change rate of the detected cylinder pressure and a fuel injection timing correction amount are calculated wherein a difference between the calculated maximum change rate and the target maximum cylinder pressure change rate decreases. The fuel injection timing is corrected with the fuel injection timing correction amount. The recirculation amount of exhaust gases is controlled using the calculated control value. A correction amount of the exhaust gas recirculation amount is calculated when the fuel injection timing correction amount exceeds a predetermined amount. The exhaust gas recirculation amount is controlled using the control value corrected with the correction amount of the exhaust gas recirculating amount.

Abstract: A control system for an internal combustion engine having a fuel injector located in a combustion chamber of the engine for injecting fuel into the combustion chamber. The fuel injection timing stored in a fuel injection timing map is retrieved according to the detected engine operating condition to determine the fuel injection timing. An actual ignition timing of the fuel injected into the combustion chamber is detected. An ignition delay of the actual ignition timing with respect to the target ignition timing, which is set according to the engine operating condition and a fuel injection timing correction amount, is calculated according to the calculated ignition delay. The fuel injection timing is corrected with the fuel injection timing correction amount, and the fuel injection is executed according to the corrected fuel injection timing.

Abstract: A control system used with an engine determines a fuel injection timing according to a detected engine operating condition and fuel injection is executed through a fuel injection valve. The target ignition timings of the fuel are set according to the detected engine operating condition and stored in a memory. An ignition delay of the actual ignition timing relative to the target ignition timing and a cetane number of the fuel are calculated. Control values of the recirculation amount of exhaust gases are set according to the detected engine operating condition and stored in the memory. The stored control value is retrieved and the recirculation amount of exhaust gases is controlled using the retrieved control value. A correction amount of the recirculation amount of exhaust gases is calculated according to the estimated cetane number and the recirculation amount of exhaust gases is controlled using the corrected control value.

Abstract: A functional RNP containing negative-strand single-stranded RNA derived from Sendai virus, which has been modified so as not to express at least one envelope protein, has been successfully prepared. An RNP comprising a foreign gene is prepared and inserted into a cell with the use of a cationic liposome, thereby successfully expressing the foreign gene.

Abstract: The present invention provides virus vectors of the family Paramyxoviridae in which the transcription start (S) sequence has been modified so as to modify the expression of genes located downstream thereof, a method for producing the vectors, and uses thereof. By measuring the transcription initiation efficiency of the S sequence of each gene carried by Sendai viruses (SeV), it was clarified that the S sequence of F gene has a significantly lower ability to promote transcription than the other three S sequences. When the S sequence of the F gene of wild type Sendai virus was substituted by the S sequence of the P/M/HN gene-type showing a high transcription initiation efficiency, the F gene of the resultant Sendai virus mutant and genes located downstream thereof show elevated expression levels. It was also revealed that this mutant proliferates more quickly than the wild type.

Abstract: The present invention provides a method for transplanting lymphohematopoietic cells into a mammal, which comprises the step of injecting cells into a bone marrow cavity, and wherein the cells have an exogenous gene encoding a receptor that induces cell proliferation in response to ligand binding. By combining intra-bone marrow transplantation (iBMT) and selective amplifier gene (SAG), marrow conditioning before the injection of the cells can be omitted. The present invention further provides a bone marrow transplant and a kit for transplanting lymphohematopoietic cells into mammals. Furthermore, the invention provides an SAG particularly suitable for such transplantation.

Abstract: The present invention provides paramyxoviral vectors encoding active ribozymes. The vectors of the present invention are suitable as vectors for gene therapy to express desired ribozymes in a broad range of tissues in vivo or ex vivo. The vectors of the present invention can be used in gene therapy for cancers and other diseases.

Abstract: A method for generating Sendai virus particles by transfecting the Sendai virus genome to a host expressing all genes for the initial viral replication has been developed, enabling the genetic manipulation of Sendai virus and effective utilization of said virus as the vector.

Abstract: The present invention provides methods for retrotransposing LINEs. The present invention relates to methods for transcribing RNAs comprising LINE 3?UTR fragments in cells, and retrotransposing these RNAs by using viral vectors to provide their LINE ORF proteins in trans. This invention also relates to methods for altering LINE retrotransposition target sites by replacing a LINE endonuclease domain with an endonuclease domain of another LINE. The methods of LINE retrotransposition of the present invention are useful for novel gene delivery.

Abstract: The present invention provides methods for producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope, using neuraminidase (NA) derived from Gram-positive bacteria. The methods comprise the steps of culturing cells producing a viral vector in the presence of an NA from Gram-positive bacteria, and recovering the produced virus. The methods of this invention enable the production of high titer virus at high cost performance. Such a viral vector is capable of transferring genes at high efficiency into cells such as blood cells and hematopoietic cells, including hematopoietic stem cells, and mucous cells including mucoepithelial cells, those not amenable to gene transfer by conventional methods, and therefore should be useful as a vector for gene therapy.

Abstract: The present invention provides methods of transducing a gene into activated T cells comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides a method of preparing T cells transduced with a foreign gene comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides T cells transduced with a foreign gene prepared by this method. The present invention enables efficient gene transduction specific to activated T cells, and is expected to be applied to immunological modification strategies using T cell-directed gene delivery.

Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Abstract: A vector expressing two foreign genes by using RRE sequence and controlling the ratio of the expression doses of these genes owing to the modification is provided. This vector, which can be provided as a lentivirus vector based on SIVagm, is constructed by modifying a virus-origin expression regulatory sequence into another expression regulatory sequence so as to eliminate the dependency on the virus-origin protein. Although this vector has a packaging signal, it has been modified so that the risk of the occurrence of wild strains due to gene recombination is lowered and no virus structural protein is expressed. This vector is highly useful as a gene therapeutic vector with a need for transferring two genes while controlling the expression doses or expression dose ration thereof.

Abstract: Use of a negative-sense RNA virus vector has enabled transfer of nucleic acid into nerve cells. The method of this invention can be used for introducing a gene efficiently into nerve cells including the central nerve tissue in gene therapy, etc.